Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | KAZ954 |
Trade Name | |
Synonyms | KAZ-954|KAZ 954 |
Drug Descriptions |
KAZ954 is a monoclonal antibody targeting ectonucleoside triphosphate diphosphohydrolase (ENTPD2), which inhibits the hydrolysis of ATP to ADP and potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): PR015). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C205683 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
KAZ954 | KAZ954 | 0 | 1 |
KAZ954 + NZV930 | KAZ954 NZV930 | 0 | 1 |
KAZ954 + Spartalizumab | KAZ954 Spartalizumab | 0 | 1 |
KAZ954 + Taminadenant | KAZ954 Taminadenant | 0 | 1 |